Aapalutamide is an orally administered selective androgen receptor inhibitor. In a post-hoc analysis of the SPARTAN study, Perez-Ruixo and colleagues assessed the relationship. between exposure to apalutamide and its active metabolite, N-desmethyl-apalutamide, with clinical efficacy and safety endpoints. A total of 21% of patients receiving apalutamide experienced dose reductions diminishing the average daily dose to 209 mg instead of 240 mg. Differences in apalutamide and N-desmethyl-apalutamide exposures after the administration of apalutamide dose of 240 mg once daily did not result in clinically relevant differences in metastasis-free survival. Skin rash and weight loss were significantly associated with apalutamide exposure, with patients who had higher exposures being more likely to experience these adverse events. These results indicate that patients experiencing adverse events linked to apalutamide treatment may benefit from dose-reduction without compromising treatment efficacy.

Natural killer (NK) cells enhance antibody-dependent cytotoxicity. In a phase I trial, Lee and colleagues assessed whether...

You do not currently have access to this content.